FrancophonIA/ELRC3.0 huggingface dataset:
English: Buprenorphine is a partial agonist at the μ (mu)-opiate receptor and chronic administration produces dependence of the opioid type.
Slovenian: Buprenorfin je delni agonist μ (mu)-opiatnega receptorja, tako da kronično dajanje povzroča opioidno odvisnost.
English: Angina Pectoris Bradycardia Myocardial infarction Palpitations Tachycardia
Slovenian: Srčne bolezni angina pektoris bradikardija miokardni infarkt palpitacije tahikardija
English: Management
Slovenian: Obvladovanje
English: Patients who are positive for viral hepatitis, on concomitant medicinal products (see section 4.5) and/or have existing liver dysfunction are at risk of accelerated liver injury.
Slovenian: Pri bolnikih, ki so pozitivni na virusni hepatitis in se sočasno zdravijo z drugimi zdravili (glejte poglavje 4.5), in/ali pri bolnikih z motenim delovanjem jeter obstaja tveganje za pospešeno poškodbo jeter.
English: • increased blood pressure, flushing
Slovenian: • povečan krvni tak, zardevanje,
English: • Keep the tablets in place under the tongue until they have completely dissolved
Slovenian: • Tablete morate imeti pod jezikom, dokler se popolnoma ne raztopijo.
English: To avoid precipitating withdrawal, induction with buprenorphine/naloxone should be undertaken when objective signs of withdrawal are evident (see section 4.2).
Slovenian: Za preprečitev odtegnitvenega sindroma je treba uvajanje zdravljenja z buprenorfinom/naloksonom izvajati šele, ko so prisotni objektivni znaki odtegnitve (glejte poglavje 4.2).
English: The dose in mg can differ between buprenorphine products and products are not directly interchangeable.
Slovenian: Prehod z drugih zdravil, ki vsebujejo buprenorfin Odmerek v miligramih se lahko med zdravili, ki vsebujejo buprenorfin, razlikuje, zato ta zdravila niso neposredno zamenljiva.
English: The effect of hepatic impairment on the pharmacokinetics of buprenorphine and naloxone were evaluated in a post-marketing study.
Slovenian: Učinek okvare jeter na farmakokinetiko buprenorfina in naloksona je bil ocenjen v študiji v obdobju trženja zdravila.
English: Patients should be monitored following medical withdrawal because of the potential for relapse.
Slovenian: Zaradi morebitnega relapsa je po medicinski odtegnitvi bolnike potrebno spremljati.
English: However, when administered intravenously to opioid-dependent patients the presence of naloxone in Zubsolv produces marked opioid antagonist effects, thereby deterring intravenous abuse.
Slovenian: Vendar pa prisotnost naloksona v zdravilu Zubsolv pri intravenskemu dajanju bolnikom, ki so odvisni od opioidov, povzroči znatne antagonistične učinke na opioidnih receptorjih, ter tako odvrača od intravenske uporabe.
English: Mild hepatic Impairment (Child-Pugh Class A) (n=9)
Slovenian: Blaga okvara jeter (Child-Pugh razred A) (n = 9)
English: Zubsolv may cause drowsiness.
Slovenian: Zdravilo Zubsolv lahko povzroča zaspanost.
English: Patients should be warned that it is extremely dangerous to self-administer non-prescribed benzodiazepines while taking this product, and should also be cautioned to use benzodiazepines concurrently with this product only as directed by their physician (see section 4.4)
Slovenian: Bolnike je treba opozoriti, da je uporaba nepredpisanih benzodiazepinov na lastno pest med jemanjem tega zdravila izjemno nevarna in da je uporaba benzodiazepinov sočasno s tem zdravilom dovoljena samo skladno z navodili njihovega zdravnika (glejte poglavje 4.4) • drugimi depresivi centralnega živčnega sistema, drugimi derivati opioidov (npr. metadon,
English: Clinical data confirm that CYP3A4 is responsible for the N-dealkylation of buprenorphine.
Slovenian: Klinični podatki potrjujejo, da je za N-dealkilacijo buprenorfina odgovoren encim CYP3A4.
English: Nervous system disorders
Slovenian: Depresija centralnega živčnega sistema
English: Tell your doctor if you have any liver problems before you start treatment with Zubsolv.
Slovenian: Če imate težave z jetri, morate o tem pred začetkom zdravljenja z zdravilom Zubsolv obvestiti zdravnika.
English: • flu-like symptoms, infection, sore throat and painful swallowing, runny nose
Slovenian: • gripi podobni simptomi, okužba, vneto grlo in boleče požiranje, izcedek iz nosu,
English: Zubsolv sublingual tablets should be used with caution in patients with moderate hepatic impairment (see sections 4.2 and 5.2).
Slovenian: Podjezične tablete zdravila Zubsolv je treba pri bolnikih z zmerno okvaro jeter uporabljati previdno (glejte poglavji 4.2 in
English: Caution is recommended when dosing patients with severe renal impairment (creatinine clearance <30 ml/min) (see sections 4.2 and 5.2).
Slovenian: Pri odmerjanju pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min) se priporoča previdnost (glejte poglavji 4.2 in 5.2).
English: Zubsolv should be used cautiously when co-administered with:
Slovenian: Zdravilo Zubsolv je treba uporabljati previdno pri sočasnem dajanju z:
English: Opioids should be used with caution in patients with hypotension, prostatic hypertrophy or urethral stenosis.
Slovenian: Pri uporabi opioidov pri bolnikih s hipotenzijo, hipertrofijo prostate ali uretralno stenozo je potrebna previdnost.
English: “11.4” on one side
Slovenian: 8,2 mm z oznako »11.4« na eni strani
English: Patients requiring a titrated daily dose > 5.7 mg buprenorphine /day may not find this regimen adequate.
Slovenian: Ta režim odmerjanja morda ne bo primeren za bolnike, ki potrebujejo prilagojen dnevni odmerek > 5,7 mg buprenorfina/dan.
English: Table 1: Treatment related adverse reactions reported in clinical trials and post-marketing surveillance of buprenorphine/naloxone
Slovenian: Preglednica 1: z zdravljenjem povezani neželeni učinki, o katerih so poročali v kliničnih preskušanjih in po začetku trženja buprenorfina/naloksona Organski sistem Zelo pogosti
English: Hepatitis Hepatitis acute Jaundice Hepatic necrosis Hepatorenal syndrome
Slovenian: žolčnika in žolčevodov hepatitis akutni hepatitis zlatenica nekroza jeter hepatorenalni sindrom
English: The dose of buprenorphine or the CYP3A4 inducer may need to be adjusted accordingly
Slovenian: Morda bo potrebna ustrezna prilagoditev odmerka buprenorfina ali induktorja CYP3A4
English: Therefore, patients should be monitored when changing between different buprenorphine containing products as differences in bioavailability (see section 5.2) may be noticeable in some individual cases.
Slovenian: Ob prehodu med različnimi zdravili, ki vsebujejo buprenorfin, je treba bolnike nadzorovati, saj so lahko v posameznih primerih opazne razlike v biološki uporabnosti (glejte poglavje 5.2).
English: It is recommended that patients receiving buprenorphine/naloxone should be closely monitored if inducers (e.g. phenobarbital, carbamazepine, phenytoin, rifampicin) are co-administered.
Slovenian: Če bolniki sočasno z buprenorfinom/naloksonom prejemajo induktorje (npr. fenobarbital, karbamazepin, fenitoin, rifampicin), jih je treba pozorno spremljati.
English: Furthermore, the use of buprenorphine/naloxone during pregnancy should be assessed by the physician.
Slovenian: Zdravnik mora poleg tega ovrednotiti uporabo buprenorfina/naloksona med nosečnostjo.
English: Taking Zubsolv
Slovenian: Zubsolv.
English: For steps of 1.4-5.7 mg buprenorphine this titration is guided by reassessment of the clinical and psychological status of the patient, and should not exceed a maximum single daily dose of 17.2 mg buprenorphine (e.g. given as 11.4 + 5.7 mg, 2 x 8.6 mg or 3 x 5.7 mg).
Slovenian: Postopno prilagajanje odmerka buprenorfina od 1,4 do 5,7 mg se izvaja s pomočjo ponovnega ocenjevanja kliničnega in psihološkega stanja bolnika ter ne sme preseči največjega posameznega dnevnega odmerka 17,2 mg buprenorfina (npr. danega kot 11,4 +
English: Injury, poisoning and procedural complications
Slovenian: Poškodbe in zastrupitve in zapleti pri posegih poškodbe vročinska kap
English: Zubsolv 0.7 mg / 0.18 mg sublingual tablets Zubsolv 1.4 mg / 0.36 mg sublingual tablets Zubsolv 2.9 mg / 0.71 mg sublingual tablets Zubsolv 5.7 mg / 1.4 mg sublingual tablets Zubsolv 8.6 mg / 2.1 mg sublingual tablets Zubsolv 11.4 mg / 2.9 mg sublingual tablets
Slovenian: Zubsolv 0,7 mg/0,18 mg podjezične tablete Zubsolv 1,4 mg/0,36 mg podjezične tablete Zubsolv 2,9 mg/0,71 mg podjezične tablete Zubsolv 5,7 mg/1,4 mg podjezične tablete Zubsolv 8,6 mg/2,1 mg podjezične tablete Zubsolv 11,4 mg/2,9 mg podjezične tablete
English: Moderate Hepatic Impairment (Child-Pugh Class B) (n=8)
Slovenian: Zmerna okvara jeter (Child-Pugh razred B) (n = 8)
English: • Full opioid agonist: adequate analgesia may be difficult to achieve when administering a full opioid agonist in patients receiving buprenorphine/naloxone.
Slovenian: • polni opiodni agonisti: pri bolnikih, ki jemljejo buprenorfin/nalokson in prejemajo polne opioidne agoniste, je težko doseči zadostno analgezijo.
English: Zubsolv 0.7 mg / 0.18 mg sublingual tablets Zubsolv 1.4 mg / 0.36 mg sublingual tablets Zubsolv 2.9 mg / 0.71 mg sublingual tablets Zubsolv 5.7 mg / 1.4 mg sublingual tablets Zubsolv 8.6 mg / 2.1 mg sublingual tablets Zubsolv 11.4 mg / 2.9 mg sublingual tablets buprenorphine / naloxone
Slovenian: Zubsolv 0,7 mg/0,18 mg podjezične tablete Zubsolv 1,4 mg/0,36 mg podjezične tablete Zubsolv 2,9 mg/0,71 mg podjezične tablete Zubsolv 5,7 mg/1,4 mg podjezične tablete Zubsolv 8,6 mg/2,1 mg podjezične tablete Zubsolv 11,4 mg 2,9 mg podjezične tablete buprenorfin/nalokson
English: 1.4 mg / 0.36 mg 4 years
Slovenian: 1,4 mg/0,36 mg 4 leta
English: Zubsolv is not interchangeable with other buprenorphine products.
Slovenian: Zdravilo Zubsolv ni zamenljivo z drugimi zdravili, ki vsebujejo buprenorfin.
English: • abnormal dreams, agitation, loss of interest, depersonalisation (not feeling like yourself),
Slovenian: • nenormalne sanje, razburjenost, izguba zanimanja, depersonalizacija (bolnik se ne počuti pri sebi), odvisnost od zdravila, pretiran občutek dobrega počutja, občutek sovražnosti,
English: • Starting treatment of Zubsolv whilst dependent on methadone: If you have been taking methadone or a long acting opioid, the dose of methadone should ideally be reduced to below 30 mg/day before beginning Zubsolv therapy.
Slovenian: Če ste jemali metadon oziroma dolgotrajno delujoč opioid, je treba odmerek metadona, če je le mogoče, zmanjšati pod 30 mg/dan, preden začnete z zdravljenjem z zdravilom Zubsolv.
English: B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Slovenian: (ODGOVORNI) ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE
English: Severe Hepatic Impairment (Child-Pugh Class C) (n=8)
Slovenian: Huda okvara jeter (Child-Pugh razred C) (n = 8)
English: Take-home doses were provided for weekends.
Slovenian: Odmerke za čez vikend so bolniki vzeli s seboj domov.
English: Store the blister safely.
Slovenian: Pretisni omot shranjujte na varnem.
English: Fold here Tear here
Slovenian: Odtrgaj tukaj
English: • Do not consume any food or drink until the tablets have completely dissolved.
Slovenian: • Dokler se tablete popolnoma ne raztopijo, ne uživajte nobene hrane ali pijače.
English: If you forget to take Zubsolv
Slovenian: Če ste pozabili vzeti zdravilo Zubsolv
English: Name and address of the manufacturer responsible for batch release
Slovenian: A. IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ Ime in naslov izdelovalca, odgovornega za sproščanje serij
English: Buprenorphine, when taken orally, undergoes first-pass metabolism with N-dealkylation and glucuroconjugation in the small intestine and the liver.
Slovenian: Absorpcija Buprenorfin pri peroralnem jemanju najprej preide skozi presnovo prvega prehoda z N-dealkilacijo ter glukuronidno konjugacijo v tankem črevesu in jetrih.
English: 11.4 mg / 2.9 mg 3 years
Slovenian: 11,4 mg/2,9 mg 3 leta
English: • CYP3A4 inhibitors: an interaction study of buprenorphine with ketoconazole (a potent inhibitor of CYP3A4) resulted in increased Cmax and AUC (area under the curve) of buprenorphine (approximately 50 % and 70 % respectively) and, to a lesser extent, of norbuprenorphine Patients receiving Zubsolv should be closely monitored, and may require dose-reduction if combined with potent CYP3A4 inhibitors (e.g. protease inhibitors like ritonavir, nelfinavir or indinavir, azole antifungals such as ketoconazole, itraconazole or macrolide antibiotics)
Slovenian: • zaviralci CYP3A4: v študiji medsebojnega delovanja buprenorfina s ketokonazolom (močnim zaviralcem encima CYP3A4) je prišlo do povečanja vrednosti Cmax in AUC (površina pod krivuljo) za buprenorfin (za približno 50 % in 70 %, v tem zaporedju) ter v manjši meri za norbuprenorfin.
English: White, capsule shaped tablets, length 10.3 mm and width 8.2 mm, debossed with “11.4” on one side.
Slovenian: Bele tablete v obliki kapsule z dolžino 10,3 mm in širino 8,2 mm, z vtisnjeno oznako »11.4« na eni strani.
English: Precipitation of opioid withdrawal syndrome
Slovenian: Povzročitev sindroma opioidne odtegnitve
English: • the concomitant use of monoamine oxidase inhibitors (MAOI) might produce exaggeration of the effects of opioids, based on experience with morphine
Slovenian: • izkušnje z morfijem kažejo, da sočasna uporaba zaviralcev monoaminooksidaze (MAO) lahko poudari učinke opioidov
English: • abdominal pain, upset stomach or other stomach discomfort, diarrhoea, flatulence, vomiting
Slovenian: • bolečine v trebuhu, razdražen želodec ali neugodje v želodcu, driska, napenjanje, bruhanje,
English: Medicinal product subject to special and restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Slovenian: B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Predpisovanje in izdaja zdravila je le na poseben recept in le s posebnim režimom (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
English: Buprenorphine/naloxone may cause severe, possibly fatal, respiratory depression in children and non-dependent persons in case of accidental or deliberate ingestion.
Slovenian: Če bi buprenorfin/nalokson nenamerno ali namenoma zaužili otroci ali druge osebe, ki niso odvisniki, bi lahko to povzročilo hudo in potencialno smrtno respiratorno depresijo.
English: White, triangular tablets, base 7.2 mm and height 6.9 mm, debossed with “1.4” on one side.
Slovenian: Bele trikotne tablete z dolžino stranice 7,2 mm in višino 6,9 mm, z vtisnjeno oznako »1.4« na eni strani.
English: - are intoxicated due to alcohol or have trembling, sweating, anxiety, confusion, or hallucinations caused by alcohol - are taking naltrexone or nalmefene for the treatment of alcohol or opioid dependence
Slovenian: - če ste alergični na buprenorfin, nalokson ali katero koli sestavino tega zdravila (navedeno v poglavju 6), - če imate hude težave z dihanjem, - če imate hude težave z jetri, - če ste omamljeni z alkoholom ali se tresete, potite, ste anksiozni (tesnobni), zmedeni ali imate halucinacije, ki jih povzroča alkohol, - če jemljete naltrekson ali nalmefen za zdravljenje odvisnosti od alkohola ali opioidov.
English: Since both buprenorphine and naloxone are extensively metabolized in liver, plasma levels were found to be higher for both buprenorphine and naloxone in patients with moderate and severe hepatic impairment after single-dose administration.
Slovenian: Ker se buprenorfin in nalokson v veliki meri presnavljata v jetrih, sta bili njuni plazemski koncentraciji po enkratnem odmerjanju višji pri bolnikih z zmerno in hudo okvaro jeter.
English: 8.6 mg / 2.1 mg 3 years
Slovenian: 8,6 mg/2,1 mg 3 leta
English: Opioids may produce orthostatic hypotension in ambulatory patients.
Slovenian: Splošna opozorila, ki se nanašajo na dajanje opioidov Opioidi lahko pri mobilnih bolnikih povzročijo ortostatsko hipotenzijo.
English: White, oval tablets, length 6.8 mm and width 4.0 mm, debossed with “.7” on one side.
Slovenian: Bele ovalne tablete z dolžino 6,8 mm in širino 4,0 mm, z vtisnjeno oznako ».7« na eni strani.
English: Co-administration during buprenorphine/naloxone treatment is contraindicated due to the potentially dangerous interaction that may precipitate a sudden onset of prolonged and intense opioid withdrawal symptoms (see section 4.3)
Slovenian: Zaradi potencialno nevarnega medsebojnega delovanja, ki lahko sproži nenaden pojav dolgotrajnih in intenzivnih simptomov odtegnitve od opioidov, je sočasno jemanje med zdravljenjem z buprenorfinom/naloksonom kontraindicirano (glejte poglavje 4.3)
English: White, diamond shaped tablets, length 9.5 mm and width 8.2 mm, debossed with “8.6” on one side.
Slovenian: Bele tablete v obliki romba z dolžino 9,5 mm in širino 8,2 mm, z vtisnjeno oznako »8.6« na eni strani.
English: • increased cough
Slovenian: • pogostejši kašelj,
English: Nephrolithiasis
Slovenian: Nalokson
English: Zubsolv contains the active substances buprenorphine and naloxone.
Slovenian: Zdravilo Zubsolv vsebuje učinkovini buprenorfin in nalokson.
English: For subjects randomised to either active treatment, dosing began with 8 mg of buprenorphine on Day 1, followed by 16 mg (two 8 mg) of buprenorphine on Day 2.
Slovenian: Za osebe, ki so bile naključno razporejene v katero koli od zdravljenj z učinkovino, se je odmerjanje začelo z 8 mg buprenorfina prvi dan, ki mu je sledilo 16 mg (dvakrat po 8 mg) buprenorfina drugi dan. Tretji dan so osebe, ki so bile naključno razporejene v skupino, ki je prejemala buprenorfin/nalokson, prešle na tablete s kombinacijo učinkovin.
English: 1.7-fold increase
Slovenian: 1,2-kratno povečanje 1,1-kratno povečanje 1,7-kratno povečanje
English: • seeing or hearing things that are not there (hallucinations)
Slovenian: To so lahko simptomi poškodbe jeter; • če slišite ali vidite stvari, ki jih ni (halucinacije).
English: Cases of acute hepatic injury have been reported in opioid-dependent addicts both in clinical trials and in post marketing adverse reaction reports.
Slovenian: Pri osebah, zasvojenih z opioidi, so tako v kliničnih preskušanjih kot v poročilih o neželenih učinkih po začetku trženja zdravila poročali o primerih akutne poškodbe jeter.
English: In rats buprenorphine has been found to inhibit lactation.
Slovenian: Ugotovili so, da buprenorfin pri podganah zavira laktacijo.
English: Alcohol may increase drowsiness and may increase the risk of respiratory failure if taken with Zubsolv.
Slovenian: Alkohol lahko ob sočasnem uživanju z zdravilom Zubsolv poveča zaspanost in tveganje dihalne odpovedi.
English: Amenorrhoea Ejaculation disorder Menorrhagia Metrorrhagia
Slovenian: Motnje reprodukcije in dojk erektilna disfunkcija amenoreja motnje ejakulacije menoragija metroragija
English: Opioids should be used with caution in patients with myxoedema, hypothyroidism, or adrenal cortical insufficiency (e.g., Addison's disease).
Slovenian: Pri uporabi opioidov pri bolnikih z miksedemom, hipotiroidizmom ali adrenokortikalno insuficienco
English: Buprenorphine misuse by someone other than the intended patient poses the additional risk of new drug dependent individuals using buprenorphine as the primary drug of abuse, and may occur if the medicine is distributed for illicit use directly by the intended patient or if the medicinal product is not safeguarded against theft.
Slovenian: Zloraba buprenorfina, ki je ne zagreši ciljni bolnik, pač pa druga oseba, predstavlja dodatno tveganje za nove odvisnike od mamil, ki buprenorfin uporabljajo kot primarno zdravilo za zlorabo.
English: Zubsolv 5.7 mg / 1.4 mg sublingual tablets
Slovenian: Zubsolv 5,7 mg/1,4 mg podjezične tablete
English: 0.7 mg / 0.18 mg
Slovenian: ZUBSOLV 0,7 mg/0,18 mg
English: Sweden
Slovenian: Uppsala Švedska
English: White, D-shaped tablets, height 7.3 mm and width 5.65 mm, debossed with “2.9” on one side.
Slovenian: Bele tablete v obliki črke D z višino 7,3 mm in širino 5,65 mm, z vtisnjeno oznako »2.9« na eni strani.
English: White, round tablets, 7 mm in diameter, debossed with “5.7” on one side.
Slovenian: Bele okrogle tablete s premerom 7 mm, z vtisnjeno oznako »5.7« na eni strani.
English: A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
Slovenian: PRILOGA II A. IZDELOVALEC (IZDELOVALCI), ODGOVOREN
English: Zubsolv 8.6 mg / 2.1 mg sublingual tablets
Slovenian: Zubsolv 8,6 mg/2,1 mg podjezične tablete
English: Influenza Infection Pharyngitis Rhinitis
Slovenian: Infekcijske in parazitske bolezni gripa okužba faringitis rinitis okužba sečil vaginalna okužba
English: • For patients receiving methadone, the dose of methadone should be reduced to a maximum of
Slovenian: • Pri bolnikih, ki prejemajo metadon, je treba pred začetkom zdravljenja z buprenorfinom/naloksonom odmerek metadona zmanjšati na največ 30 mg/dan.
English: Zubsolv 1.4 mg / 0.36 mg sublingual tablets
Slovenian: Zubsolv 1,4 mg/0,36 mg podjezične tablete
English: Overall, buprenorphine plasma exposure increased approximately 3-fold in patients with severely impaired hepatic function, while naloxone plasma exposure increased 14-fold with severely impaired hepatic function.
Slovenian: 0,2-kratno povečanje 3,2-kratno povečanje 14,0-kratno povečanje Na splošno se je pri bolnikih s hudo okvarjenim delovanjem jeter plazemska izpostavljenost buprenorfinu povečala za približno 3-krat, plazemska izpostavljenost naloksonu pa za 14-krat.
English: Sublingual tablet
Slovenian: 30 podjezičnih tablet
English: Zubsolv 2.9 mg / 0.71 mg sublingual tablets
Slovenian: Zubsolv 2,9 mg/0,71 mg podjezične tablete
English: Zubsolv 11.4 mg / 2.9 mg sublingual tablets
Slovenian: Zubsolv 11,4 mg/2,9 mg podjezične tablete
English: • spinning sensation
Slovenian: • občutek vrtenja,
English: Zubsolv tablet description Zubsolv tablet debossing
Slovenian: Vtisnjene oznake na tabletah zdravila Zubsolv
English: Patients should not swallow or consume food or drink until the tablet is completely dissolved.
Slovenian: Dokler se tableta popolnoma ne raztopi, bolnik ne sme pogoltniti sline ali zaužiti hrane oziroma pijače.
English: • have low blood pressure, enlarged prostate gland or difficulties passing water because of narrowing of the urethra
Slovenian: • če imate nizek krvni tlak, povečano prostato ali težave z uriniranjem zaradi zožene sečnice, • če imate premalo aktivno žlezo ščitnico, kar lahko povzroči utrujenost ali povečano telesno maso,
English: Each 8.6 mg / 2.1 mg sublingual tablet contains 8.6 mg buprenorphine (as hydrochloride) and 2.1 mg naloxone (as hydrochloride dihydrate).
Slovenian: Ena podjezična tableta 8,6 mg/2,1 mg vsebuje 8,6 mg buprenorfina (v obliki klorida) in 2,1 mg naloksona (v obliki klorida dihidrata).
English: Zubsolv 1.4 mg / 0.36 mg sublingual tablets buprenorphine / naloxone
Slovenian: Zubsolv 1,4 mg/0,36 mg podjezične tablete buprenorfin/nalokson
English: Posology
Slovenian: Buprenorfin
English: Zubsolv 11.4 mg / 2.9 mg sublingual tablets buprenorphine / naloxone
Slovenian: Zubsolv 11,4 mg/2,9 mg podjezične tablete buprenorfin/nalokson
English: Each 0.7 mg / 0.18 mg sublingual tablet contains 0.7 mg buprenorphine (as hydrochloride) and 0.18 mg naloxone (as hydrochloride dihydrate).
Slovenian: Ena podjezična tableta 0,7 mg/0,18 mg vsebuje 0,7 mg buprenorfina (v obliki klorida) in 0,18 mg naloksona (v obliki klorida dihidrata).
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING PACK OF 7, 28, and 30 TABLETS 0.7 mg / 0.18 mg STRENGTH
Slovenian: PAKIRANJE PO 7, 28, in 30 TABLET Z JAKOSTJO 0,7 mg / 0,18 mg
English: Zubsolv 0.7 mg / 0.18 mg sublingual tablets
Slovenian: Zubsolv 0,7 mg/0,18 mg podjezične tablete
English: Blood and lymphatic system disorders
Slovenian: Bolezni krvi in limfatičnega sistema anemija levkocitoza levkopenija limfadenopatija trombocitopenija
English: 7 sublingual tablets 28 sublingual tablets 30 sublingual tablets
Slovenian: 28 podjezičnih tablet
English: Citric acid anhydrous Sodium citrate Microcrystalline cellulose Croscarmellose sodium Sucralose
Slovenian: 6.1 Seznam pomožnih snovi manitol brezvodna citronska kislina natrijev citrat mikrokristalna celuloza premreženi natrijev karmelozat sukraloza levomentol brezvodni koloidni silicijev dioksid natrijev stearilfumarat